|This message contains images. If you don't see images, click here to view.|
Advertise in this news brief.
In search of a hair loss cure: How close are we, really?
While losing a little off the top isn't the social exile that it once was, the experience of hair loss is still stressful and frustrating for most people.
About 70 percent of men and 40 percent of women go through some degree of hair thinning as they age, almost usually as a result of androgenic alopecia, otherwise known as male or female pattern baldness.
| Share this article:
New noninvasive technique to detect skin cancers
In a major breakthrough, a new noninvasive technique that allows clinicians to accurately detect various forms of skin cancer has been developed.
Technology advances melanoma diagnosis, treatment
New technology on the market and in development offers the potential to revolutionize the detection of melanoma. Photography, dermoscopy, in vivo confocal microscopy and immunotherapy all hold promise thanks to recent advances, according to an expert who spoke about this topic at the 73rd annual meeting of the American Academy of Dermatology in San Francisco earlier this year.
Signal soothing relief with 5 new products from glō therapeutics designed to provide serious calming action to even the most sensitive skin. All are free of dyes, fragrance, parabens, gluten, nuts and soy.
Researchers learn to measure aging process in young adults
Looking around at a 20th high school reunion, you might notice something puzzling about your classmates. Although they were all born within months of each other, these 38-year-olds appear to be aging at different rates.
Oxybutynin deemed effective treatment for hyperhidrosis
British Journal of Dermatology via Medical Xpress
Dr. Martine Schollhammer from University Hospital in Brest, France, and colleagues examined the effectiveness and tolerance of low-dose oxybutynin for hyperhidrosis in a randomized placebo-controlled trial. The researchers found that for improving the Hyperhidrosis Disease Severity Scale, oxybutynin was superior to placebo, with improvement of at least one point on the HDSS for 60 percent of oxybutynin-treated patients versus 27 percent of placebo-treated patients.
Rapid responders may offer clues to optimize immune therapy
Studying rapid responders to immunotherapy and researching therapeutic targets for melanoma subtypes, like uveal melanoma are some focal points for clinicians who treat melanoma, according to doctors who spoke at the 9th annual Canadian melanoma conference, Whistler, British Columbia, Canada.
Experimental psoriasis drug shows promise
HealthDay News via Health On the Net Foundation
Preliminary trial results suggest that an experimental psoriasis drug may control the chronic skin disease better than the current standard treatment.
Laser resurfacing at the time of rhytidectomy
Plastic and Reconstructive Surgery
Laser resurfacing with simultaneous rhytidectomy has been used to augment aesthetic results and decrease overall patient recuperative time, yet presents a potential dual insult to the microvasculature supply of facial skin flaps. This study describes the authors' experience with rhytidectomy and simultaneous laser resurfacing.
Voluma XC satisfactory results last up to 2 years
A multicenter, single-blind randomized, controlled study to examine the efficacy of Juvéderm Voluma XC — an HA filler for the correction of midface volume deficit (MVD) — from the patients' perspectives has shown high patient satisfaction up to two years following treatment. The study, conducted by Dr. Julius Few, included subjects treated at 15 sites in the U.S. and Canada from August 2009 to June 2012.
Missed an issue of Warfield Weekly Update? Click here to visit Warfield Weekly Update archive page.
Clinical rebounding triad after corticosteroid discontinuation
HealthDay News via Medical Xpress
A subgroup of patients with dermatitis who discontinue topical corticosteroids after long-term treatment have clinical rebounding triad manifestations, according to a study published in the July issue of the Journal of Dermatology.
FDA approves Galderma's Restylane Lyft for cheek augmentation
Plastic Surgery Practice
The U.S. Food and Drug Administration has approved Restylane Lyft with lidocaine for cheek augmentation. Restylane Lyft, formerly marketed as Perlane-L, is also approved to correct and smooth the nasolabial folds.
Missed last week's issue? See which articles your colleagues read most.
What is your Membership Worth?
Answer: More than double what you invest!
As an SDSS member, you are eligible to SAVE $100 on NCEA Certified Records Verification. Email firstname.lastname@example.org Sign up here. This is a $175 value.
NOT A MEMBER — Join Now!
NCEA-sponsored Prep Class — Aug. 24
Face & Body
Northern California Spa Conference & Expo
San Jose, California
NCEA Certified Pres Class
Monday, Aug. 24
10 a.m. to 5 p.m., Room TBD
• Members: $125
• Nonmembers: $149
Includes: Complimentary NCEA Certified Records Verification ($175 value)
*Membership status must be current on day of event.
Save the Date: NETT Teacher Training
Mark your calendar to attend the National Esthetic Teacher Training Conference:
Long Beach Convention Center - Sept. 19
Philadelphia Convention Center - Oct. 24
To receive registration information, text "NCEA" to 22828.
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063